Gabapentin Global Market Report 2025

The gabapentin market size has grown strongly in recent years. It will grow from $2.78 billion in 2024 to $3.01 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the rising prevalence of epilepsy, an increase in cases of neuropathic pain, heightened awareness of neurological disorders, a growing elderly population, and the expanded use of generic anticonvulsant medications.

The gabapentin market size is expected to see strong growth in the next few years. It will grow to $4.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to the rising demand for chronic pain management, increasing approvals of gabapentin formulations, improved healthcare access in developing regions, a greater emphasis on personalized medicine, and the growing burden of neurological disorders. Key trends expected during this period include advancements in drug delivery systems, the integration of gabapentin into combination therapies, technology-driven R&D for neuropathic pain, progress in extended-release formulations, and developments in pharmacogenomics applications.

The rising prevalence of epilepsy is expected to drive the growth of the gabapentin market in the coming years. Epilepsy is a neurological disorder marked by recurring seizures caused by abnormal electrical activity in the brain. The increase in epilepsy cases is largely attributed to the growing aging population, as advancing age heightens the risk of neurological conditions that can lead to seizures. Gabapentin helps manage epilepsy by stabilizing abnormal nerve activity in the brain and reducing signals that trigger seizures. It acts by targeting calcium channels to prevent seizure episodes. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a U.S. government agency, reported that around 2.9 million U.S. adults aged 18 and older were living with active epilepsy in 2022, reflecting a 1.08% increase compared to 2021. As a result, the growing incidence of epilepsy is contributing to the expansion of the gabapentin market.

Leading companies in the gabapentin market are concentrating on developing advanced formulations, such as bioequivalent tablets, to improve therapeutic efficacy and broaden treatment options for neurological disorders. Bioequivalent tablets are generic formulations that deliver the same amount of active ingredient into the bloodstream at the same rate and extent as the branded version, ensuring equivalent safety and effectiveness. For example, in March 2024, Strides Pharma Science Limited, an India-based pharmaceutical company, launched Gabapentin Tablets USP in 600 mg and 800 mg strengths following approval from the United States Food & Drug Administration (USFDA), aiming to expand its neurology portfolio in the U.S. market. This advanced gabapentin formulation offers improved bioavailability, accurate dosing, and convenient administration, supporting more consistent therapeutic results, better symptom control, and ease of use in long-term treatment. Gabapentin Tablets USP, 600 mg, provide versatile therapeutic benefits, effectively managing various neurological conditions such as neuropathic pain and partial seizures through dependable dosing and clinically validated efficacy.

In September 2023, Adalvo, a Malta-based pharmaceutical company, partnered with Lotus Pharmaceutical to improve lives by providing accessible and innovative neurological treatments. This collaboration focuses on introducing a convenient, once-daily treatment for postherpetic neuralgia through the launch of Gabapentin ER in South Korea. The initiative aims to address unmet medical needs while strengthening their presence in the neurology market. Lotus Pharmaceutical, based in Taiwan, is the manufacturer of gabapentin extended-release tablets.

Major players in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC.

North America was the largest region in the gabapentin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gabapentin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gabapentin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gabapentin is a prescription drug primarily used to manage nerve pain, epilepsy, and restless legs syndrome. It works by affecting nerve signals and brain chemicals to control seizures and alleviate nerve pain. It is commonly prescribed for nerve-related conditions such as pain from shingles and diabetic neuropathy. Gabapentin helps stabilize brain activity and decrease abnormal nerve excitability.

Gabapentin is available in both generic and branded forms. Generic versions contain the same active ingredients and dosages as branded ones, offering a more cost-effective but equally effective treatment option. It comes in multiple dosage forms, including tablets, capsules, and oral solutions, and is distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Its primary applications include treatment for epilepsy, neuropathic pain, restless legs syndrome, and additional related conditions.

The gabapentin market research report is one of a series of new reports that provides gabapentin market statistics, including the gabapentin industry global market size, regional shares, competitors with the gabapentin market share, detailed gabapentin market segments, market trends, opportunities, and any further data you may need to thrive in the gabapentin industry. This gabapentin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gabapentin market consists of sales of gabapentin immediate-release, gabapentin extended-release, and oral solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.